GlassScriptPhysician profile
Natalie Yanes
NPI 1457776940
$27,252.66
in general payments reported to CMS, 2019-2025
40 companies · $3,946 in 2025
The $3,946 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,470 · 2020: $3,480 · 2021: $3,880 · 2022: $4,397 · 2023: $3,975 · 2024: $4,106 · 2025: $3,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $55.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,970.95 |
| Education | $55.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,478.34 | 2019-2025 | Krystexxa, Evenity, Enbrel |
| Abbvie INC. | $3,364.83 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,652.95 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $2,573.19 | 2019-2025 | |
| Janssen Biotech, INC. | $2,492.46 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $1,836.58 | 2020-2025 | Acthar |
| Lilly USA, LLC | $1,401.19 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $1,221.44 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $1,185.82 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Glaxosmithkline, LLC. | $1,185.25 | 2019-2025 | Benlysta |
| Pfizer INC. | $871.21 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $759.22 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $655.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $505.83 | 2019-2025 | Orencia |
| Depuy Synthes Sales INC. | $375.92 | 2019-2025 | Orthovisc, Monovisc, Peak |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Yanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.